Objectives: The aim of this study was to evaluate the effectiveness and safety of an intravitreal bevacizumab injection (IVB) in the treatment of retinopathy of prematurity (ROP). Methods: The medical records of patients who had received IVB treatment for ROP between January 2014 and October 2018. Anatomical and functional outcomes were evaluated. The Denver II Developmental Screening Test was administered and fluorescein angiography (FA) was performed in some cases. Results: Thirty-eight eyes of 19 infants were included in the study. An IVB injection was administered to 9 infants with aggressive posterior ROP (APROP) disease (Group 1), 6 infants with any stage ROP with plus disease in zone I (Group 2), and 4 infants with stage 2-3 ROP with plus disease in zone II (Group 3). Complete retinal vascularization was observed in 24 eyes of 12 infants who received a single dose of bevacizumab without any additional treatment. Recurrence of the disease was observed in 12 eyes of 6 infants diagnosed with APROP and laser photocoagulation was performed. FA was performed to 5 IVB patients whose parents approved the procedure. The Denver II Developmental Screening Test was administered to all of the participants, and the test outcomes were consistent with the corrected age of the children, though 2 infants demonstrated a developmental delay in gross motor development tasks. Overall, good anatomical and functional results were obtained. Conclusion: IVB is an effective and relatively safe treatment modality for infants with ROP; however, prospective studies are required to provide more detailed information about systemic side effects.
1. Howson CP, Kinney MV, McDougall L, Lawn JE; Born Too Soon Preterm Birth Action Group. Born too soon: preterm birth matters. Reprod Health 2013;10:S1.
2. No authors listed. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Preliminary Results. Arch Ophthalmol 1988;106:471–9.
3. Vander JF, McNamara JA, Tasman W, Brown GC. Revised indications for early treatment of retinopathy of prematurity. Arch Ophthalmol 2005;123:406–7.
4. Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831–8.
5. Hillier RJ, Connor AJ, Shafiq AE. Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series. Br J Ophthalmol 2018;102:260–4.
6. Martínez-García SM, Hernández-Da Mota SE, Rubio-Rangel A, Rojas-Flores I, Vieyra-López ME, Martínez-Castellanos MA, et al. Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series Cir Cir 2017;85:478–84.
7. Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics 2016;137.e20153218.
8. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–9.
9. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233–50.
10. Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014;121:2212–9.
11. Anlar B, Yalaz K. Denver II Gelişimsel Tarama Testi. Türk çocuklarına uyarlanması ve standardizasyonu HÜTF Ped. Ankara: Nöroloji Bilim Dalı; 1995. p. 1–43.
12. Kim R, Kim YC. Posterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection in posterior retinopathy of prematurity. J Ophthalmol 2014;2014:257286.
13. Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004;24:507–11.
14. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6–10.
15. Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. Pediatric Eye Disease Investigator Group. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology 2018;125:1961–6.
16. Lorenz B, Stieger K, Jäger M, Mais C, Stieger S, Andrassi-Darida M. Retinal Vascular Development with 0.312 mg Intravitreal Bevacizumab to Treat Severe Posterior Retinopathy of Prematurity: A Longitudinal Fluorescein Angiographic Study. Retina 2017;37:97–111.
17. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology 2011;118:176–83.
18. Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 2015;15:20.
19. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603–15.
20. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000–6.
21. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–33.
22. Martínez-Castellanos MA, Schwartz S, Hernández-Rojas ML, Kon-Jara VA, García-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 2013;33:329–38.
23. Howe TH, Sheu CF, Hsu YW, Wang TN, Wang LW. Predicting neurodevelopmental outcomes at preschool age for children with very low birth weight. Res Dev Disabil 2016;48:231–41.
24. Thébaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007;91:291–7.
25. Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month followup results from Turkey. Graefes Arch Clin Exp Ophthalmol 2015;253:1677–83.
26. Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 2014;98:507–12.
27. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061–3.
28. Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed 2013;98:F327–F33.
29. Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023–34.
30. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 2006;26:S11–S5.
31. Ekinci DY, Çelik K. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus 2020;57:54–60.